Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | TSPO | P30536 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8421119 | 0.85 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPK1TSHRSMN1; SMN2 | |
| SCHEMBL7086389 | 0.85 | ALDH1A1 (0.55) | ALDH1A1HPGDMAPK1TSHRSMN1; SMN2 | |
| SCHEMBL1644965 | 0.84 | MAPK1 (0.59) | ALDH1A1HPGDMAPK1TSHRSMN1; SMN2 | |
| SCHEMBL27401813 | 0.82 | GAA (0.48) | ALDH1A1HPGDSMN1; SMN2HTTPOLB | |
| SCHEMBL3150784 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HPGDMAPK1TSHRSMN1; SMN2 | |
| SCHEMBL7055476 | 0.82 | ALDH1A1 (0.57) | ALDH1A1HPGDMAPK1TSHRSMN1; SMN2 | |
| SCHEMBL30168125 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HPGDMAPK1TSHRSMN1; SMN2 | |
| SCHEMBL4196369 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPK1TSHRSMN1; SMN2 | |
| SCHEMBL7466732 | 0.81 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL6475322 | 0.81 | ALDH1A1 (0.55) | ALDH1A1HPGDMAPK1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056937-B2 | Sulfonylquinoxalone derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | claimed |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| US-5849746-A | Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT1D receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 1998-12-15 | — | — | US | claimed |
| CN-110579936-B | Thermally developable photosensitive material and medical film using the same | 柯尼卡美能达株式会社 | 2023-10-27 | — | — | CN | disclosed |
| CN-110579936-A | Heat-developable photosensitive material and medical film using the same | 柯尼卡美能达株式会社 | 2019-12-17 | — | — | CN | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-1493819-B1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | UBE INDUSTRIES (JP) | 2014-11-12 | — | — | EP | disclosed |
| CN-101040053-B | Process for producing optically active (S or R) -beta-amino acid and optically active (R or S) -beta-amino acid ester, and beta-amino acid 2-alkoxyethyl ester and optically active (S or R) -beta-amino acid 2-alkoxyethyl ester | UBE INDUSTRIES | 2013-04-24 | — | — | CN | disclosed |
| CN-102994606-A | Process for production of optically active (S)- or (R)-beta-amino acids and optically active (R)- or (S)-beta -amino acid esters, and optically active (S)- or (R)-2-alkoxyethyl esters of beta-amino acids. | UBE INDUSTRIES | 2013-03-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| CN-101248184-B | Process for production of optically active (S or R)-a-amino acid or optically active (S or R)-a -amino acid ester | UBE INDUSTRIES | 2013-01-16 | — | — | CN | disclosed |
| EP-0796258-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1997-09-24 | — | — | EP | disclosed |
| US-5656642-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| WO-1997018201-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-22 | — | — | WO | disclosed |
| WO-1996023785-A1 | SUBSTITUTED 1,4-PIPERAZINE-HETEROARYL DERIVATIVES AS 5-HT1D RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996017842-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-06-13 | — | — | WO | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
| CN-1104412-A | Peripheral Vasodilating agent containing N-acylated 4-amino piperidine derivatives as active ingredients | OTSUKA PHARMA CO LTD (JP) | 1995-06-28 | — | — | CN | disclosed |
| EP-0650476-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | BDKRB2, BDKRB1, HRH2 | ALDH1A1 2364/4885HPGD 73/4885MAPK1 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.